Volume 19, Number 3—March 2013
CME ACTIVITY - Research
Clinical and Therapeutic Features of Pulmonary Nontuberculous Mycobacterial Disease, Rio de Janeiro, Brazil
Karla Gripp Couto de Mello, Fernanda C.Q. Mello, Liamar Borga, Valeria Rolla, Rafael S. Duarte, Elizabeth P. Sampaio, Steven M. Holland, D. Rebecca Prevots, and Margareth P. Dalcolmo
Table 2
Coexisting medical conditions for174 patients with PNTM, Brazil, 1993–2011*
| Coexisting condition† | No. (%) patients |
|---|---|
| None | 59 (33.9) |
| Bronchiectasis | 38 (21.8) |
| Chronic obstructive pulmonary disease | 36 (20.7) |
| Cardiovascular disease | 27 (15.5) |
| AIDS | 17 (9.8) |
| Diabetes | 17 (9.8) |
| Asthma | 8 (4.6) |
| Hepatitis C | 8 (4.6) |
| Cancer, excluding lung cancer | 6 (3.4) |
| Gastroesophageal reflux | 6 (3.4) |
| Rheumatioid arthritis | 3 (1.7) |
| Nonviral cirrhosis | 2 (1.1) |
| Hansen disease | 2 (1.1) |
| Lupus | 2 (1.1) |
| Anemia falciforme | 1 (0.57) |
| Silicosis | 1 (0.57) |
| Marfan syndrome | 1 (0.57) |
| Kidney transplantation and immunosupression | 1 (0.57) |
| Mitral valve prolapse | 1 (0.57) |
*PNTM, pulmonary nontuberculous mycobacterial disease.
†Patients may have exhibited >1 coexisting condition.
Page created: February 13, 2013
Page updated: February 22, 2013
Page reviewed: February 22, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.